Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Neoplasms 3Colorectal Neoplasms 2Skin Neoplasms 1Skin Diseases 1Rectal Neoplasms 1Rectal Diseases 1Neoplasm Metastasis 1Melanoma 1Lung Neoplasms 1Intestinal Neoplasms 1Intestinal Diseases 1Gastrointestinal Neoplasms 1Gastrointestinal Diseases 1Digestive System Neoplasms 1Digestive System Diseases 1Colonic Neoplasms 1Colonic Diseases 1Carcinoma, Non-Small-Cell Lung 1

Interventions

selpercatinib 2binimetinib 2Crizotinib 2ulixertinib 1tremelimumab 1trastuzumab biosimilar HLX02 1trametinib 1sapanisertib 1repotrectinib 1relatlimab 1pralsetinib 1pertuzumab 1palbociclib 1osimertinib 1omipalisib 1larotrectinib 1ipatasertib 1erdafitinib 1encorafenib 1durvalumab 1defactinib 1dabrafenib 1copanlisib 1ceritinib 1capmatinib 1capivasertib 1brigatinib 1adavosertib 1X-Rays 1Trastuzumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has announcements × Lung Neoplasms × encorafenib × Clear all
NCT03915951 2026-03-24

An Open-label Study of Encorafenib + Binimetinib in Patients With BRAFV600-mutant Non-small Cell Lung Cancer

Pfizer

Phase 2 Completed
98 enrolled 18 charts 1 FDA
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡